- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01138878
HIV Testing in Non-traditional Settings Study (HINTS)
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, SE5 9RS
- Kings College Hospital NHS Foundation Trust
-
London, United Kingdom, E9 6SR
- Homerton University NHS Foundation Trust
-
London, United Kingdom, SW10 9NH
- Chelsea and Westminster NHS Foundation Trust
-
London, United Kingdom, W14 9NP
- North End Medical Centre, Hammersmith and Fulham Primary Care NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
For patient pre-study and intra-study: All patients aged 16-65 (not know already to be HIV positive) attending the healthcare setting (Primary Care centre, Emergency Department, Acute Care Unit, Medical Outpatient Clinic) before or during the twelve week HIV testing pilot programme
For Staff pre-study and post-study: All members of staff (HCP, Allied Health Professionals and Admin/Clerical) working within the healthcare settings examined before and during the implementation of the HIV testing programme
Description
Inclusion Criteria (patient study only):
- aged 16 - 65 and accessing relevant healthcare setting for care
- able to consent to HIV test
- able to provide adequate contact details
- to complete written questionnaire: adequate written English
- to participate in focus group discussion (pre-study group)/participate in semi-structured telephone interview (intra-study group): ability to provide fully informed consent
Exclusion Criteria:
- known HIV positive
- unable to provide adequate contact details
- unable to provide consent (to HIV test and/or participation in questionnaire/focus group/semi-structured interview studies)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patient pre-study group
A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
|
Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
|
Staff pre-study group
A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
|
Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
|
Patient intra-study group
A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
|
Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
Telephone interview administered to patients offered an HIV test during the pilot period
|
Post-study staff group
A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
|
Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
(1) Feasibility of delivering opt-out HIV testing in ED/ACU/OPD/Primary Care setting
Time Frame: At end of twelve week testing period at each site
|
At end of twelve week testing period at each site
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
(2) Estimate of prevalence of undiagnosed HIV with risk factor/demographic assessment
Time Frame: At end of twelve week testing period
|
At end of twelve week testing period
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jane Anderson, MBBS FRCP, Homerton University Hospital NHS Foundation Trust
- Principal Investigator: Melinda Tenant-Flowers, MBBS FRCP MSc, Kings College Hospital NHS Foundation Trust
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1.4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on Questionnaire
-
H. Lee Moffitt Cancer Center and Research InstituteSan Diego State University; University of Minnesota; University of ArizonaCompletedAnxiety | Psychological StressUnited States
-
Centre Hospitalier Universitaire de NiceCompletedGeneral Population | TDAH | Children Aged 5 to 18 YearsFrance
-
Minneapolis Veterans Affairs Medical CenterUnited States Department of DefenseCompletedLower Limb Amputation Below Knee (Injury) | Lower Limb Amputation Above Knee (Injury)United States
-
NSABP Foundation IncNational Cancer Institute (NCI)Completed
-
Imperial College LondonRoyal Marsden NHS Foundation Trust; University College London Hospitals; The... and other collaboratorsCompleted
-
Stanford UniversityRecruitingAstigmatism | Nearsightedness | FarsightednessUnited States
-
University of LiegeCompletedCritical Illness | Covid19 | Psychological Stress | FamilyBelgium
-
Imperial College Healthcare NHS TrustNot yet recruitingCervical Myelopathy
-
Rabin Medical CenterCompleted
-
University of PalermoRecruitingFamilial Mediterranean Fever | Non-celiac Gluten SensitivityItaly